FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2463260778> ?p ?o ?g. }

• W2463260778 endingPage "22301" @default.
• W2463260778 startingPage "22288" @default.
• W2463260778 abstract "Nuclear factor E2-related factor 2 (Nrf2) is considered a promising target against diabetic complications such as cardiovascular diseases and diabetic nephropathy. Herein, we investigated the effects of a potential Nrf2 modulator, salvianolic acid A (SAA), which is a natural polyphenol, on diabetes-associated macrovascular and renal injuries in streptozotocin-induced diabetic mice. Given that lowering glucose is the first objective of diabetic patients, we also examined the effects of SAA combined with metformin (MET) on both complications. Our results showed that SAA significantly increased the macrovascular relaxation response to acetylcholine and sodium nitroprusside in diabetic mice. Interestingly, treatment with SAA alone only provided minor protection against renal injury, as reflected by minor improvements in impaired renal function and structure, despite significantly reduced oxidative stress observed in the diabetic kidney. We demonstrated that decreased oxidative stress and NF-κB p65 expression were associated with SAA-induced expression of Nrf2-responsive antioxidant enzymes heme oxygenase-1 (HO-1), NAD(P)H dehydrogenase (quinone) 1 (NQO-1), and glutathione peroxidase-1 (GPx-1) in vivo or in vitro, which suggested that SAA was a potential Nrf2 modulator. More significantly, compared with treatment with either SAA or MET alone, we found that their combination provided further protection against the macrovascular and renal injury, which was at least partly due to therapeutic activation of both MET-mediated AMP-activated protein kinase and SAA-mediated Nrf2/antioxidant-response element pathways. These findings suggested that polyphenol Nrf2 modulators, especially combined with drugs activating AMP-activated protein kinase, including hypoglycemic drugs, are worthy of further investigation to combat diabetic complications. Nuclear factor E2-related factor 2 (Nrf2) is considered a promising target against diabetic complications such as cardiovascular diseases and diabetic nephropathy. Herein, we investigated the effects of a potential Nrf2 modulator, salvianolic acid A (SAA), which is a natural polyphenol, on diabetes-associated macrovascular and renal injuries in streptozotocin-induced diabetic mice. Given that lowering glucose is the first objective of diabetic patients, we also examined the effects of SAA combined with metformin (MET) on both complications. Our results showed that SAA significantly increased the macrovascular relaxation response to acetylcholine and sodium nitroprusside in diabetic mice. Interestingly, treatment with SAA alone only provided minor protection against renal injury, as reflected by minor improvements in impaired renal function and structure, despite significantly reduced oxidative stress observed in the diabetic kidney. We demonstrated that decreased oxidative stress and NF-κB p65 expression were associated with SAA-induced expression of Nrf2-responsive antioxidant enzymes heme oxygenase-1 (HO-1), NAD(P)H dehydrogenase (quinone) 1 (NQO-1), and glutathione peroxidase-1 (GPx-1) in vivo or in vitro, which suggested that SAA was a potential Nrf2 modulator. More significantly, compared with treatment with either SAA or MET alone, we found that their combination provided further protection against the macrovascular and renal injury, which was at least partly due to therapeutic activation of both MET-mediated AMP-activated protein kinase and SAA-mediated Nrf2/antioxidant-response element pathways. These findings suggested that polyphenol Nrf2 modulators, especially combined with drugs activating AMP-activated protein kinase, including hypoglycemic drugs, are worthy of further investigation to combat diabetic complications." @default.
• W2463260778 created "2016-07-22" @default.
• W2463260778 creator A5002481588 @default.
• W2463260778 creator A5004150390 @default.
• W2463260778 creator A5030234400 @default.
• W2463260778 creator A5033681865 @default.
• W2463260778 creator A5034702019 @default.
• W2463260778 creator A5066716873 @default.
• W2463260778 creator A5068899498 @default.
• W2463260778 creator A5083101583 @default.
• W2463260778 creator A5086094981 @default.
• W2463260778 creator A5086710510 @default.
• W2463260778 creator A5088967912 @default.
• W2463260778 date "2016-10-01" @default.
• W2463260778 modified "2023-09-28" @default.
• W2463260778 title "Effects of the Nrf2 Protein Modulator Salvianolic Acid A Alone or Combined with Metformin on Diabetes-associated Macrovascular and Renal Injury" @default.
• W2463260778 cites W1166587220 @default.
• W2463260778 cites W1453170402 @default.
• W2463260778 cites W1524891965 @default.
• W2463260778 cites W1545732697 @default.
• W2463260778 cites W1575885381 @default.
• W2463260778 cites W1964423369 @default.
• W2463260778 cites W1966971152 @default.
• W2463260778 cites W1976438491 @default.
• W2463260778 cites W1976653479 @default.
• W2463260778 cites W1982368955 @default.
• W2463260778 cites W2004356390 @default.
• W2463260778 cites W2006173764 @default.
• W2463260778 cites W2006727651 @default.
• W2463260778 cites W2012022623 @default.
• W2463260778 cites W2012519498 @default.
• W2463260778 cites W2015729133 @default.
• W2463260778 cites W2022100059 @default.
• W2463260778 cites W2022568070 @default.
• W2463260778 cites W2027989920 @default.
• W2463260778 cites W2028897622 @default.
• W2463260778 cites W2029133250 @default.
• W2463260778 cites W2031565266 @default.
• W2463260778 cites W2038478235 @default.
• W2463260778 cites W2048328683 @default.
• W2463260778 cites W2052799097 @default.
• W2463260778 cites W2053350368 @default.
• W2463260778 cites W2065325705 @default.
• W2463260778 cites W2069159655 @default.
• W2463260778 cites W2076108526 @default.
• W2463260778 cites W2077150739 @default.
• W2463260778 cites W2078593792 @default.
• W2463260778 cites W2082866035 @default.
• W2463260778 cites W2084141237 @default.
• W2463260778 cites W2088104904 @default.
• W2463260778 cites W2097668381 @default.
• W2463260778 cites W2098828894 @default.
• W2463260778 cites W2100123437 @default.
• W2463260778 cites W2110664743 @default.
• W2463260778 cites W2112948259 @default.
• W2463260778 cites W2113965152 @default.
• W2463260778 cites W2123946565 @default.
• W2463260778 cites W2125114619 @default.
• W2463260778 cites W2125236267 @default.
• W2463260778 cites W2125670865 @default.
• W2463260778 cites W2126764927 @default.
• W2463260778 cites W2128188021 @default.
• W2463260778 cites W2134172788 @default.
• W2463260778 cites W2134907909 @default.
• W2463260778 cites W2140524866 @default.
• W2463260778 cites W2153059926 @default.
• W2463260778 cites W2160347055 @default.
• W2463260778 cites W2163301537 @default.
• W2463260778 cites W2164994583 @default.
• W2463260778 cites W2166383881 @default.
• W2463260778 cites W2171553260 @default.
• W2463260778 cites W2319046289 @default.
• W2463260778 cites W3176496431 @default.
• W2463260778 cites W952491933 @default.
• W2463260778 doi "https://doi.org/10.1074/jbc.m115.712703" @default.
• W2463260778 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5064007" @default.
• W2463260778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27417135" @default.
• W2463260778 hasPublicationYear "2016" @default.
• W2463260778 type Work @default.
• W2463260778 sameAs 2463260778 @default.
• W2463260778 citedByCount "42" @default.
• W2463260778 countsByYear W24632607782016 @default.
• W2463260778 countsByYear W24632607782017 @default.
• W2463260778 countsByYear W24632607782018 @default.
• W2463260778 countsByYear W24632607782019 @default.
• W2463260778 countsByYear W24632607782020 @default.
• W2463260778 countsByYear W24632607782021 @default.
• W2463260778 countsByYear W24632607782022 @default.
• W2463260778 countsByYear W24632607782023 @default.
• W2463260778 crossrefType "journal-article" @default.
• W2463260778 hasAuthorship W2463260778A5002481588 @default.
• W2463260778 hasAuthorship W2463260778A5004150390 @default.
• W2463260778 hasAuthorship W2463260778A5030234400 @default.
• W2463260778 hasAuthorship W2463260778A5033681865 @default.
• W2463260778 hasAuthorship W2463260778A5034702019 @default.
• W2463260778 hasAuthorship W2463260778A5066716873 @default.
• W2463260778 hasAuthorship W2463260778A5068899498 @default.
• W2463260778 hasAuthorship W2463260778A5083101583 @default.

• next